Treatment Clinical Trials for Non-Small Cell Lung Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for non-small cell lung cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 426-450 of 505

  • TVB-2640 for the Treatment of Patients with Metastatic or Advanced KRAS Mutant Non-Small Cell Lung Cancers

    This phase II trial studies how well TVB-2640 works for the treatment of patients with KRAS mutant non-small cell lung cancers that have spread to other places in the body (metastatic or advanced). TVB-2640 belongs to a class of drugs called fatty acid synthase inhibitors (FASN inhibitors). FASN inhibitors may slow or stop tumor growth by interfering with the body’s (and the tumor’s) ability to use FASN.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • A Study to Allow Continued Dosing and / or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

    This is an open-label extension study (Extension Study) designed to allow patients to continue to receive poziotinib treatment who have had previous exposure to poziotinib and / or are still receiving clinical benefit from treatment, as judged by the Investigator or treating physician. Patients must begin treatment in this study within 28 days after their last dose of poziotinib. This extension protocol is intended to provide clinical benefit of poziotinib to patients who are responding to treatment. The additional treatment is optional and voluntary.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

    Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at least 1 hour before their first meal of the day
    Location: 3 locations

  • Bronchoscopic Laser Ablation of Peripheral Lung Tumors

    As our population ages and we diagnose early lung cancer in patients who cannot undergo surgery due to multiple medical conditions, there is growing interest in minimally invasive modalities to treat these tumors. In this study we are assessing the ability of bronchoscopic laser ablation to kill the cancer cells in these tumors. Patients will undergo bronchoscopy (a tube-like instrument inserted through the mouth to view the inside of the trachea, air passages, and lungs). A thin catheter will be passed through the wind-pipes and into the lung tumor with computed tomography guidance. A laser probe is then passed through this catheter and it is used to destroy the tumor with heat. Patients will then undergo lung surgery with resection of the tumor, and the resected specimen will be reviewed to describe the amount of tumor-kill produced by the laser.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Combination Therapy With Intravenous VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and HNSCC

    This is a phase I / II safety run-in study designed to determine the safety of VSV-IFNβ-NIS in combination with pembrolizumab, followed by dose expansion in patients with refractory NSCLC or HNSCC. The safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with the approved dose of pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or HNSCC. The optimal dose (recommended phase 2 dose, RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Durvalumab, Tremelimumab, and Selumetinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer

    This phase I / II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating patients with stage IV non-small cell lung cancer or that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving durvalumab, tremelimumab and selumetinib may work better in treating patients with non-small lung cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Nivolumab, Ipilimumab, and Paclitaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well nivolumab, ipilimumab, and paclitaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Biological therapies, such as paclitaxel, use substances made from living organisms that may kill tumor cells by blocking blood flow to the tumor. Giving nivolumab, ipilimumab, and paclitaxel may work better in treating patients with non-small cell lung cancer.
    Location: Duke University Medical Center, Durham, North Carolina

  • CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of autologous dendritic cell-adenovirus CCL21 vaccine (CCL21-gene modified dendritic cell vaccine) combined with intravenous pembrolizumab, and to see how well they work in treating patients with stage IV non-small cell lung cancer. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving CCL21-gene modified dendritic cell vaccine with pembrolizumab may work better in treating patients with stage IV non-small cell lung cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Nivolumab and Ramucirumab for the Treatment of Recurrent, Advanced, or Metastatic Non-Small Cell Lung Cancer

    This phase II trial studies the effect of nivolumab and ramucirumab on patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body (advanced / metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab may block new blood vessel growth to reduce tumor growth. Giving nivolumab and ramucirumab may work better at controlling disease progression in non-small cell lung cancer patients than nivolumab therapy alone.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

    This is a phase 3, open-label, 3-cohort, randomized study to compare the safety and efficacy of N-803 in combination with the current standard of care (experimental arms) versus standard of care alone (control arms), as first-line treatment for subjects with stage 3 or 4 advanced or metastatic NSCLC. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.
    Location: 3 locations

  • A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors

    This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
    Location: M D Anderson Cancer Center, Houston, Texas

  • APX005M, Nivolumab, and Cabiralizumab in Treating Patients with Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Cancer Who Have Progressed on Anti-PD1 / PDL-1 Therapy

    This phase I / Ib trial studies the best dose and side effects of APX005M, and how well it works in combination with nivolumab and cabiralizumab in treating patients with melanoma, non-small cell lung cancer and renal cell cancer that have spread to other places in the body and have progressed on anti-PD -1 / PD-L 1 therapy. Monoclonal antibodies, such as APX005M, nivolumab and cabiralizumab, interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Radiation Therapy and Chemotherapy in Treating Patients with Stage II-IV Non-small Cell Lung Cancer and the Effect of Treatment on Patient-Reported Outcomes

    This phase III trial studies how well radiation therapy and chemotherapy work in treating patients with stage II-IV non-small cell lung cancer and to see the effect of treatment on patient-reported outcomes. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving accelerated radiation therapy within shorter time and chemotherapy may work better than standard radiation therapy in treating patients with non-small-cell lung cancer and may improve patient outcomes.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

    This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months. Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Pembrolizumab and Itacitinib in Treating Patients with Previously Untreated PD-L1 Positive Stage IV Non-Small Cell Lung Cancer

    This phase II trial studies the side effects of itacitinib when given with itacitinib, and to see how well they work in treating patients with stage IV non-small cell lung cancer expressing PD-L1. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab with itacitinib may work better in treating patients with stage IV non-small cell lung cancer expressing PD-L1.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Nivolumab, Ipilimumab, and Nintedanib in Treating Patients with Advanced or Metastatic Non-small Cell Lung Cancer

    This phase I / II trial studies the best dose of nintedanib when given together with nivolumab and ipilimumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced or metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nintedanib, nivolumab and ipilimumab may work better in treating patients with non-small cell lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

    This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
    Location: 2 locations

  • Ipilimumab and Nivolumab in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well ipilimumab and nivolumab work in treating patients with non-small cell lung cancer that is stage IIIB, stage IV, or that has come back. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Combination of TATE and PD-1 Inhibitor in Liver Cancer

    This is a single center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (either nivolumab or pembrolizumab). Patients with four types of cancers will be enrolled, hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), metastatic gastric cancer and advanced non-small cell lung cancer. All enrolled patients need to have liver lesions.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

    Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States. Most people with lung cancer are already in the advanced stages of the disease by the time they see a doctor. Researchers want to see if combining an approved drug with two new drugs can help. Objective: To study if tetrahydrouridine-decitabine (THU-DAC) with pembrolizumab is safe and effective in people with non-small cell lung cancer that cannot be removed by surgery. Eligibility: People 18 years and older who have NSCLC that cannot be removed by surgery Design: Participants will be screened with - Medical history - Physical exam - Blood and urine tests - Tests of heart and lung function They may have a small tumor sample taken (biopsy). They may have tumor scans. Before starting treatment, participants will repeat the screening tests. They will also give a stool sample. The study will be done in 3-week cycles for up to 6 cycles. - Participants will take the 2 study drugs by mouth 3-5 days a week. - Participants will get pembrolizumab in a vein for 30 minutes 1 day each cycle. Participants will keep a study medication diary. During cycle 1, participants will have blood taken multiple times on days 1 and 2. Every 3 cycles, participants will repeat screening tests. Participants will have a mandatory tumor biopsy. When they finish treatment, participants will have a physical exam and blood tests.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Pevonedistat and Docetaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well pevonedistat and docetaxel work in treating patients with stage IV non-small cell lung cancer or non-small cell lung cancer that has come back. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

    This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
    Location: 2 locations

  • Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

    This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • MAGE-A4ᶜ¹º³²T for Multi-Tumor

    This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid / round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.
    Location: 2 locations

  • A Study Evaluating MM-310 in Patients With Solid Tumors

    MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.
    Location: Duke University Medical Center, Durham, North Carolina